Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
salmefamol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Salmefamol is a sympathomimetic bronchodilator with predominantly beta-2 adrenergic agonist activity. It was investigated for the treatment of airway obstruction and compared to drugs such as salbutamol, adrenaline, and atropine. Clinical studies demonstrated that salmefamol provides significant bronchodilation, with its effects lasting longer than salbutamol and without associated tachycardia. Its mechanism involves relaxation of bronchial smooth muscle via beta-2 receptor activation, increasing cyclic AMP and thereby producing smooth muscle relaxation in the airways[3][4]. Its development and clinical evaluation date back to the 1970s.
- Brand names
- salmefamol
- Other names
- salmefamol
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on salmefamol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on salmefamol.